AZN vs. GSK, ITH, SOPH, HCM, INDV, GRI, SLS, ERGO, SLN, and AMYT
Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include GSK (GSK), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), HUTCHMED (HCM), Indivior (INDV), Grainger (GRI), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Silence Therapeutics (SLN), and Amryt Pharma (AMYT). These companies are all part of the "pharmaceutical products" industry.
AstraZeneca vs. Its Competitors
AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
AstraZeneca has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.
67.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 56.9% of GSK shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by company insiders. Comparatively, 0.2% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
AstraZeneca pays an annual dividend of GBX 3.14 per share and has a dividend yield of 0.0%. GSK pays an annual dividend of GBX 0.62 per share and has a dividend yield of 0.0%. AstraZeneca pays out 59.0% of its earnings in the form of a dividend. GSK pays out 75.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
AstraZeneca presently has a consensus target price of GBX 9,660, indicating a potential downside of 18.45%. GSK has a consensus target price of GBX 1,637.50, indicating a potential upside of 12.31%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than AstraZeneca.
In the previous week, GSK had 3 more articles in the media than AstraZeneca. MarketBeat recorded 6 mentions for GSK and 3 mentions for AstraZeneca. GSK's average media sentiment score of 0.29 beat AstraZeneca's score of -0.20 indicating that GSK is being referred to more favorably in the news media.
AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.
Summary
AstraZeneca beats GSK on 10 of the 18 factors compared between the two stocks.
Get AstraZeneca News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
AstraZeneca Competitors List
Related Companies and Tools
This page (LON:AZN) was last updated on 9/1/2025 by MarketBeat.com Staff